Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US88023B1035
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG01MZQYJF9
TEM
Tempus AI, Inc.
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $BBLL
NAME
Tempus AI, Inc.
ISIN
US88023B1035
TICKER
TEM
MIC
XNAS
REUTERS
TEM.OQ
BLOOMBERG
TEM US
Mon, 24.08.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-PH (pulmonary hypertension), an AI-enabled software device that analyzes standard 12-lead electrocardiograms (ECGs) for signs associated with pulmonary hypertension. Tempus ECG-PH is the third FDA-cleared d...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Thu, 06.08.2026       Tempus AI
US88023B1035

Tempus joins as a second commercial laboratory partnership to support oncology-focused access within CellCarta's CDx Accelerator Model.MONTREAL, Aug. 6, 2026 /PRNewswire/ -- CellCarta, a global CRO laboratory supporting the biopharmaceutical industry, today announced a strategic collaboration with Tempus AI, Inc. (NASDAQ: TEM). Under the agreement...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.08.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced study results demonstrating that PRISM2, a multimodal slide-level pathology foundation model developed in collaboration with researchers from Microsoft, can perform clinically important diagnostic tasks usi...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.07.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended June 30, 2026. “Q2 was another exceptional quarter for us,” said Eric Lefkofsky, Founder and CEO of Tempus. “Our strategy is working given the investments we have made in AI over the...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.07.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of its OneOme pharmacogenomics (PGx) testing solution, delivering advanced genetic insights to optimize medication safety, dosing and toxicity risk assessment. Following its acquisition...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.07.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that it has entered into a definitive agreement to acquire Personalis, Inc. (NASDAQ: PSNL). The acquisition will expand Tempus' capabilities in minimal residual disease (MRD) and enhance its ability to supp...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.07.2026       Tempus AI
US88023B1035

Tempus, a technology company leading the adoption of AI to advance precision medicine, today highlighted results of the Articulate Pro study, published in Nature Digital Medicine, evaluating the use of AI to assist pathologists in prostate biopsy reporting. The study was a real-world evaluation of the Paige Prostate Suite, an integral part of th...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.07.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the second quarter ended June 30, 2026, on Thursday, July 30, 2026. The company will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the results and provide a...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Thu, 25.06.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a research collaboration with Angiosarcoma Awareness, Inc. to accelerate data-driven research in angiosarcoma, one of the rarest and most aggressive cancers. Angiosarcoma is a rare malignant tumor that start...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.06.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced publication of successful multi-site validation of its software, which received U.S. Food and Drug Administration clearance in 2024 for predicting the one-year risk of atrial fibrillation or flutter (AF). The study, titled...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 09.06.2026       Tempus AI
US88023B1035

Ambry Genetics, a leader in clinical genomic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced peer-reviewed research demonstrating the potential for variant-specific RNA testing to provide greater clarity for patients who receive a variant of uncertain significance (VUS) result from exome testing. The study, publi...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Fri, 05.06.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Goldman Sachs 47th Annual Global Healthcare Conference. Tempus Founder and CEO Eric Lefkofsky will participate in a fireside chat at 2:00 p.m. ET on Monday, June 8. A live webcast of the co...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Wed, 03.06.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, Yale New Haven Hospital (YNHH) and Memorial Sloan Kettering Cancer Center (MSK) today announced the launch of a digital pathology IMS Open-Source Consortium (“IMS Consortium”). Designed to accelerate the democratization and standardization...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Mon, 01.06.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the upcoming clinical availability of xH, a next-generation sequencing (NGS) test that uses a whole-genome sequencing (WGS) approach for the detection of actionable oncologic targets in peripheral blood and bone marrow samp...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Sun, 31.05.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of the next-generation of Lens, its pioneering agentic AI platform designed to accelerate drug development and research. This evolution seamlessly connects Tempus’ multimodal data, AI tooling and computational in...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Sat, 30.05.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of the PRECISION Challenge, a national initiative engineered to accelerate the next generation of oncology breakthroughs leveraging its foundational model. The PRECISION Challenge aims to unlock breakthroughs in...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Sat, 30.05.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the introduction of Tempus Preview, an application providing rapid, clinically significant insights that close the gap between the time of order and delivery of insights. Representing a significant paradigm shift in precisi...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Fri, 29.05.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the latest results from its mission to build Multimodal Foundation Models at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Tempus has been building novel biological foundation models and agentic work...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Fri, 29.05.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a tumor-only indication for its xT CDx next-generation sequencing platform. With this expanded label, Tempus is the first laboratory to hold FDA comp...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Thu, 28.05.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a significant expansion of new indications to its AI-enabled Next platform ahead of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Next establishes a new category of "real-time clinical intelligence"...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Wed, 27.05.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a major technological upgrade to Tempus Hub, its AI-enabled smart physician platform. Tempus is making available its advanced, next-generation generative AI clinical co-pilot directly in Hub to power an agent-first experien...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Tue, 26.05.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that 37 abstracts have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO®) Annual Meeting. The event will take place May 29 - June 3, 2026 in Chicago, Illinois. “This year’s ASCO Annua...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Thu, 21.05.2026       Tempus AI
US88023B1035

Tempus AI, Inc., a leader in artificial intelligence and precision medicine, today announced the clinical launch of the ArteraAI Prostate Test (mHSPC). The CLIA-certified and CAP-accredited prognostic test will be fully integrated into the Tempus platform, providing urologists and oncologists with a digital pathology solution that helps inform per...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Thu, 14.05.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new initiative with Bristol Myers Squibb (NYSE: BMY). This collaboration aims to leverage AI, multimodal real-world data and data science techniques to optimize clinical trial designs and enhance the Probability of Techni...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Mon, 11.05.2026       Tempus AI
US88023B1035

Ambry Genetics, a leader in clinical genomic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced that its CARE Program (Comprehensive, Assessment, Risk, and Education) has been awarded “Best Overall Health Informatics Solution” in the 10th Annual MedTech Breakthrough Awards. The global program recognizes excell...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Fri, 08.05.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the pricing of $400.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the “Notes”) in a private placement (the “Offering”) to persons reasonably believed to be qual...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.05.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced its intent to offer, subject to market conditions and other factors, $350.0 million aggregate principal amount of Convertible Senior Notes due in 2032 (the “Notes”) in a private placement (the “O...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Tue, 05.05.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2026. Revenue of $348.1 million, up 36.1% year-over-year Diagnostics revenue of $261.1 million, representing 34.7% growth year-over-year, driven by On...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Wed, 29.04.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that the company will host an Investor Day on Friday, May 29, 2026. The event will start at 8:00 a.m. CT / 9:00 a.m. ET and will feature Tempus’ leadership team, including, Founder and CEO Eric Lefkofsky, Chief Financial Of...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Tue, 28.04.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company advancing precision medicine through the practical application of artificial intelligence, today announced it has been named to TIME’s 10 Most Influential Health and Life Science Companies of 2026. The inaugural TIME100 Companies: Industry Leaders list, an expansion of the TIME100 Most Influentia...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.04.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and the Keck School of Medicine of USC and Keck Medicine of USC, today announced a multi-faceted collaboration aimed at transforming patient care and accelerating research through the power of data and AI. This collaboration is designed to...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.04.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the first quarter ended March 31, 2026 on Tuesday, May 5, 2026. The company will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the results and provide a busi...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.04.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Predicta Biosciences, a precision oncology company developing novel diagnostic solutions for deep molecular characterization of hematologic malignancies with a focus on circulating tumor cells, today announced the commercial expansion...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.04.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acceptance of 31 abstracts—including one oral presentation—for the American Association for Cancer Research (AACR) Annual Meeting 2026 taking place April 17–22 in San Diego. “The research that Tempus is presenting at...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.04.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of an automated clinical update service designed to support guideline-concordant care by placing patients on an "active follow-up" track. This integrated workflow provides clinicians with ongoing therapy monitori...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced an expanded, multi-year collaboration with Gilead Sciences, Inc. (Nasdaq: GILD) aimed at building and advancing Gilead’s oncology pipeline. To date, Gilead has leveraged Tempus’ extensive repository of de-identified multi...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Wed, 08.04.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, will present at the 25th Annual Needham Virtual Healthcare Conference, taking place April 13-16. Tempus’ Chief Financial Officer Jim Rogers, will participate in a fireside discussion at the conference on Tuesday, April 14 at 11:45 am ET....
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from the ALERT (Addressing undertreatment and heaLth Equity in aortic stenosis and mitral regurgitation using an integrated ehR plaTform) trial, which were recently presented at the American College of Cardiology’s...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Tue, 17.03.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Blood Cancer United® (formerly The Leukemia & Lymphoma Society), the largest global nonprofit focused on blood cancer patient support, research, and advocacy, today announced a strategic collaboration to develop a comprehensive, pa...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Wed, 11.03.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the publication of a new study in JCO Precision Oncology highlighting how advanced features of comprehensive genomic profiling (CGP) expand treatment options for cancer patients in community oncology settings. The study, co...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Tue, 03.03.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Merck, known as MSD outside of the United States and Canada, today announced an expanded, multi-year collaboration aimed at accelerating the discovery and development of precision medicine biomarkers and supporting Merck’s oncology and...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.02.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Morgan Stanley Technology, Media, and Telecom Conference on Tuesday, March 3 in San Francisco. Eric Lefkofsky, Tempus Founder and CEO, will participate in a fireside chat at 9:15 AM PST. Th...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.02.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter and year ended December 31, 2025. Fourth quarter revenue of $367.2 million, up 83.0% year-over-year with 33.5% organic growth (excluding Ambry) Diagnostics revenue of...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Wed, 18.02.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of its new HRD-RNA algorithm. This next-generation model represents a significant improvement in identifying Homologous Recombination Deficiency (HRD), providing a more robust, functional assessment of tumor biol...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.02.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a collaboration with Median Technologies (EPA: ALMDT) to bring Median’s proprietary eyonis® LCS to the Tempus Pixel platform. This collaboration empowers clinical workflows with a powerful tool to support informed diagnosti...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Tue, 10.02.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2025 on Tuesday, February 24, 2026. The company will hold the earnings conference call at 4:30 pm ET. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Wed, 04.02.2026       Tempus AI
US88023B1035

Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced its contribution to new research leveraging Multiplexed Assays of Variant Effect (MAVEs) studies to advance interpretation of hereditary cancer-linked genetic variants, published in Nature Communications. Led by...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Mon, 02.02.2026       Tempus AI
US88023B1035

Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced the completion of its one-millionth DNA/RNA test, underscoring the company’s commitment to diagnostic accuracy. A decade ago, in an industry first, Ambry Genetics pioneered paired DNA/RNA testing for hereditary cancer...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Tue, 27.01.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from a new study demonstrating that its algorithmic test, Immune Profile Score (IPS), more accurately predicts outcomes for patients receiving immune checkpoint inhibitors (ICIs) than conventional biomarkers, includ...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink
Wed, 21.01.2026       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of Paige Predict, a suite of cutting-edge digital pathology applications that analyze hematoxylin and eosin (H&E) whole slide images to help inform testing decisions. The AI-powered solution is designed to pr...
Read more
Tempus AI
Technical Analysis Termsheets Terminal
Permalink